News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
This approval has come from the company's finished dosage form manufacturing facility
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Subscribe To Our Newsletter & Stay Updated
